

Graeme C Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8049294/publications.pdf>

Version: 2024-02-01

25
papers

603
citations

623699

14
h-index

610883

24
g-index

28
all docs

28
docs citations

28
times ranked

636
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 0/microdosing approaches: time for mainstream application in drug development?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 801-818.	46.4	55
2	Metabolism and Disposition of Vilanterol, a Long-Acting β_2 -Adrenoceptor Agonist for Inhalation Use in Humans. <i>Drug Metabolism and Disposition</i> , 2013, 41, 89-100.	3.3	50
3	Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1185-1200.	2.4	47
4	Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 524-532.	2.4	40
5	Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 14.	2.4	37
6	Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 955-961.	2.0	35
7	European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry. <i>Bioanalysis</i> , 2012, 4, 2669-2679.	1.5	29
8	AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , 2011, 3, 393-405.	1.5	20
9	Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1070-1081.	3.3	20
10	New Frontiers in Accelerator Mass Spectrometry (AMS): Recommendation for Best Practices and Harmonization from Global Bioanalysis Consortium Harmonization Team. <i>AAPS Journal</i> , 2014, 16, 357-359.	4.4	19
11	Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. <i>ATLA Alternatives To Laboratory Animals</i> , 2018, 46, 335-346.	1.0	17
12	Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum. <i>Bioanalysis</i> , 2016, 8, 1297-1305.	1.5	16
13	Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans. <i>Drug Metabolism and Disposition</i> , 2014, 42, 415-430.	3.3	15
14	An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1457-1468.	3.3	14
15	Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 775-781.	4.7	14
16	Determination of Salmeterol in Rat and Dog Plasma by High-Performance Liquid Chromatography with Fluorescence Detection. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 323-325.	3.3	13
17	Application of ^{14}C -Accelerator MS in pharmaceutical development. <i>Bioanalysis</i> , 2015, 7, 513-517.	1.5	12
18	An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , 2011, 3, 407-410.	1.5	10

#	ARTICLE	IF	CITATIONS
19	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 482-489.	2.4	9
20	Pharmacokinetics, Excretion, and Mass Balance of [¹⁴ C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men. Clinical Pharmacology in Drug Development, 2018, 7, 901-910.	1.6	9
21	Pharmacokinetics and ADME Characterization of Intravenous and Oral [¹⁴ C]-Linerixibat in Healthy Male Volunteers. Drug Metabolism and Disposition, 2021, 49, 1109-1117.	3.3	8
22	Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination. Clinical Pharmacology in Drug Development, 2021, 10, 1419-1431.	1.6	6
23	Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently. Clinical Pharmacology in Drug Development, 2019, 8, 188-197.	1.6	5
24	AMS in drug development: Exploring the current utility of AMS and future opportunities for absolute bioavailability and ADME investigations. , 2020, , 185-210.		4
25	Abstract 3773: Absolute bioavailability of BRAF inhibitor GSK2118436: Use of a microtracer study in patients with cancer. Cancer Research, 2012, 72, 3773-3773.	0.9	1